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pollution. At the same time, underdiagnosis and the large number 
of cases of cancers not being detected makes the situation more 
alarming.3,4
Methods: A detailed search was conducted from national5 and 
international6 databases related to chronic disease care in India and 
globally to identify publicly released reports relevant to chronic dis-
eases such as diabetes, cancer, and cardiovascular disease, with more 
emphasis and focus on diabetes and cancer.
Results: The prevalence of diabetes has increased 10-fold between 
1971 and 2000.6 It is expected to increase to 101.2 million by 2030,7 
and 77.2 million people in India are said to have prediabetes.8 More 
than 20% of the population in India have at least 1 chronic disease 
and > 10% have > 1 chronic disease.9 According to the World Health 
Organization, if 1 adult in a low-income family has diabetes, as much 
as 25% of family income may be devoted to diabetes care.10 In an 
industrialized country such as Germany, due to lifestyle changes, it 
is expected that there will be a > 20% increase in new cases of cancer 
between 2010 and 2030.11 Awareness level, knowledge of disease 
symptoms, and screening practices were the key attributes evaluated 
in a study of breast cancer.3 It was observed among the participants 
that 56% had not heard of and 65% were not practicing breast 
self-examination. According to Ernst and Young, baseline cost of 
treatment (estimated Indian Rupees 300,000–400,000 lakhs) being 
higher than the annual house hold income for > 80% to 85% of 
households in India, cancer poses a significant threat to the Indian 
population.3 With the launch of sodium glucose co-transporter 2 
inhibitors and teneligliptin, oral drugs have taken diabetes care to the 
next level, which has shown improved glycemic control and reduc-
tion in glycosylated hemoglobin.12,13 Key risk factors (eg, alcohol per 
capita consumption in adults aged > 15 years) has increased by 55% 
between 1992 and 2012.3 Prevalence of all forms of tobacco use in 
India in 2015 was 17%, and it is one of the key factors associated 
with the increased risk of head and neck, lung, and bladder cancers.
Conclusions: Despite the steep increase expected in chronic diseases, 
India’s health care professional and infrastructure shortage is one of 
the major reasons for the country’s high mortality rate. However, the 
public sector’s lackadaisical performance due to limited investments 
and suboptimal utilization of available resources has hampered the 
growth of health care facilities. The growing burden of noncommuni-
cable diseases (NCDs)/communicable diseases is the leading cause of 
death pertaining to the ageing population, high calorie consumption, 
and low physical activity levels, accounting for 60% of all deaths in 
India. In addition, NCDs/communicable diseases account for ~40% 
of hospital stays and nearly 35% of all recorded outpatient depart-
ment visits. An ageing population and changes in societal behavior 
are contributing to a steady increase in these common and costly 
long-term health problems. The middle class is growing, and with 
urbanization accelerating, people are adopting a more sedentary 
lifestyle. This is pushing obesity rates and cases of diseases such as 
diabetes upward. The government’s low spending on health care 
places much of the burden on patients and their families, however, 
as evidenced by the country’s out-of-pocket spending rate, one of the 
world’s highest. Although the government has taken significant meas-
ures to improve access to quality care, it has also seen the emergence 
of innovative delivery models by private players to address growing 
chronic care demands. Technology (telemedicine) has a key role to 
play. Advancements in precise detection and diagnosis of disease 
will go far to minimize the cost of treating chronic conditions. The 
economic burden is further diminished due to poor health, as the 
probability of dying due to chronic diseases is 26% among the most 
productive years (ie, the 30- to 70-year-old age group). It is estimated 
that the increasing NCD burden is expected to lead to as much as US$ 
4.58 trillion loss of output between 2012 and 2030. Cardiovascular 
diseases are the major contributors (48%) to the economic burden.
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Two decades of the TRIPS (Trade Related Intellectual Properties) 
agreement aimed at strengthening the “monopoly” rights of innova-
tors and creators has brought in visible gains for the investors bank-
ing on intellectual property rights for trade and commerce across 
the nation states. However, such an agreement and implementation 
spree has been reluctant to answer the question of access to medi-
cines to vast majority of the population, including that of the devel-
oped countries. Although adherence to the standards of TRIPS and 
up- gradation to ‘TRIPS Plus” has been the central focus of various 
bilateral and multilateral talks for investment and trade among trad-
ing blocks, the issue of “access” finds a muted response. A decade 
ago in the year 2007, the World Intellectual Property Organization 
(WIPO) adapted the WIPO development agenda endorsed by the 
member states, which led to the adoption of “45 Development 
Agenda Recommendations” and thereupon the establishment of the 
Committee on Development and Intellectual Property,1 which reig-
nited the hope of shaping the intellectual property agenda to balance 
“access versus monopoly.” However, in the intervening decade, the 
rise of the Anti-Counterfeiting Trade Agreement, the Trans-Pacific 
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Partnership, the Transatlantic Free Trade Area/Transatlantic Trade 
and Investment Partnership, and the Trade in Services Agreement 
has bypassed the momentum created by the WIPO Development 
Agenda in addressing the reformation of the dominant discourse of 
Patent Regime focusing sideling the “access” issues of public health.
The central issue is that of the old patent regime, which advo-
cates that “monopoly” rights lead to “innovation” and thereby will 
address the public health issues versus the counterview that “monop-
oly” rights itself is not a linear solution to public health but needs to 
use it as an “appropriate intervention tool” to spur innovation. Thus, 
the “monopoly” question needs to be subjugated to the final question 
of “access” of drugs for all for a better public health.
This article aims to track and disseminate the recent developments 
on the question of the access versus monopoly debate from the emerg-
ing agreements outside the TRIPS and Development Agenda dialogue 
and its impact on the future of public health.
Disclosure of Interest: None declared.
Reference
1. Development Agenda for WIPO. http://www.wipo.int/ip-development/
en/agenda/. Accessed April 11, 2016.
PublicAtion biAS
V. Strüver
Hochschule Hannover, Hannover, Germany
Background: According to the Declaration of Helsinki, as well as 
the Statement on Public Disclosure of Clinical Trial Results of the 
World Health Organization, every researcher has the ethical obliga-
tion to publish research results on all trials with human participants 
in a complete and accurate way within 12 months after the end of 
the trial.1,2 Nevertheless, for several reasons, not all research results 
are published in an accurate way in case they are released at all. This 
phenomenon of publication bias may not only create a false impres-
sion on the reliability of clinical research business, but it may also 
affect the evidence of clinical conclusions about the best treatments, 
which are mostly based on published data and results.
Objectives: The aim of this article was to present different types of 
publication bias with regard to authors, peer reviewers, and editors. 
Already implemented approaches for a reduction in the publication 
bias phenomenon will be provided to strengthen confidence in the 
clinical research business.
Methods: Literature on publication bias for this narrative review 
article was identified by searching the PubMed database using the 
key words “publication bias in clinical research.” The search was 
limited to articles available as free full-text papers with publication 
dates later than 2010. Likewise, a Google search with the same key 
words was performed.
Results: Based on the reviewed literature, publication bias can be 
classified into 3 different types. The first type can be defined as pub-
lication bias, which occurs through the author before the submis-
sion of the manuscript to a journal in terms of nonpublication or 
incomplete publication of negative research results. Both other types 
describe publication bias after submission of the manuscript to a 
journal. In these cases, either the peer reviewer or the editor of a 
journal can cause bias during the publication process. For reducing 
the publication bias phenomenon in clinical research, most of the 
leading journals meanwhile insist on a registration of the study in 
public registries such as clinicaltrials.gov as a condition for successful 
publication.3 Also, the implementation of a blinded peer-reviewing 
process, in which the peer reviewer will do the review without know-
ing any author details, represents an improvement in publication bias.
Conclusions: The phenomenon of publication bias not only occurs 
before submission of manuscripts, but it may also happen after sub-
mission to a journal.4 It still forms an issue in discussions about 
evidence-based medicine. Thus, publication of trial results is required 
by internationally applicable guidance, and ongoing discussions are 
needed to keep attention by stakeholders to achieve a greater trans-
parency in the area of clinical research.
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The United States Department of Health and Human Services is 
charged with improving the health, safety, and well-being of all 
Americans. Since 2004, when former President George W. Bush 
set a goal for all Americans to have an electronic health record by 
2014, the Office of the National Coordinator (ONC) for Health 
Information Technology under the Department of Health and Human 
Services has been steadily making progress. By moving from paper 
to electronic health records, many benefits can be achieved, includ-
ing enhanced patient safety, improved care coordination, increased 
patient participation, practice efficiencies, and cost savings. The 
vision for 2024 as stated in an ONC report is an “interoperable 
health information technology (IT) ecosystem that makes the right 
data available to the right people at the right time across products 
and organizations in a way that can be relied upon and meaningfully 
used by recipients.”1
At the heart of a highly functional interoperable health infor-
mation technology ecosystem is accurate patient identity. Ensuring 
patient identity is essential for patient safety and quality of care. 
Accurate patient identification is the foundation for successfully link-
ing patient records within an integrated health care delivery system 
and across the health care ecosystem.2 The first of 5 building blocks in 
achieving ONC’s vision for 2024 tackles the need for standards that 
address essential services for interoperability, which include methods 
to accurately match individuals, providers, and their information 
across data sources.3 Furthermore, health care organizations need to 
ensure that a robust information governance program is implemented 
to address patient identity integrity.
Key words: electronic health record, health care, health informa-
tion technology, information governance, Office of the National 
Coordinator, patient identity.
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